- Home
- CHI vs MRVI Comparison
CHI vs MRVI Comparison
Compare CHI & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHI | MRVI |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CHI | MRVI |
|---|---|---|
| Price | $12.21 | $7.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 130.2K | ★ 4.6M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | N/A | $12.54 |
| Revenue Next Year | N/A | $7.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.26 | $2.55 |
| 52 Week High | $13.50 | $9.42 |
Technical Indicators
Market Signals| Indicator | CHI | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 31.13 | 47.43 |
| Support Level | $11.97 | $5.54 |
| Resistance Level | $12.13 | $7.44 |
| Average True Range (ATR) | 0.22 | 0.33 |
| MACD | -0.07 | -0.14 |
| Stochastic Oscillator | 10.18 | 17.23 |
Price Performance
Historical ComparisonAbout CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.